ProCE Banner Activity

Phase III ATLANTIS: Lurbinectedin + Doxorubicin vs CAV or Topotecan in Relapsed SCLC

Slideset Download
Conference Coverage
In this phase III trial, the combination of lurbinectedin plus doxorubicin was not associated with a survival benefit over standard chemotherapy in patients with relapsed SCLC.

Released: September 17, 2021

Expiration: September 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme